New Heart Failure Medications 2025

New Heart Failure Medications 2025. Nice has today (18 may 2023) issued final draft guidance which recommends dapagliflozin (also called forxiga and made by astrazeneca) as an option for adults with symptomatic chronic. The aim of this esc guideline is to help health professionals manage people with heart failure (hf) according to the best available evidence.

This article leverages efforts of the heart failure collaboratory and the scientific community to discuss the critical need for innovative trial designs, important concepts in clinical trials in the. The primary result showed that sotagliflozin treatment cut the combined rate of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart.